Table 3. Univariate analysis of prognostic variables (n=33).
| Variables | Category | Alive | Death | Odds ratio (95% confidence interval) | p-value |
|---|---|---|---|---|---|
| Age (yr) | <40 | 25 (80.6) | 6 (19.4) | 0 | 1.000 |
| ≥40 | 2 (100) | 0 (0) | |||
| Antecedent pregnancy | Mole | 4 (66.7) | 2 (33.3) | 0.478 (0.161–1.422) | 0.398 |
| Abortion | 6 (75.0) | 2 (25.0) | |||
| Term | 17 (89.5) | 2 (10.5) | |||
| Interval from index pregnancy (mo) | ≤12 | 14 (82.4) | 3 (17.6) | 1.077 (0.184–6.319) | 1.000 |
| >12 | 13 (81.3) | 3 (18.8) | |||
| Serum β-hCG (IU/L) | <105 | 18 (78.3) | 5 (21.7) | 0.400 (0.040–3.955) | 0.640 |
| ≥105 | 9 (90.0) | 1 (10.0) | |||
| Renal metastases | No | 22 (84.6) | 4 (15.4) | 2.200 (0.311–15.548) | 0.584 |
| Yes | 5 (71.4) | 2 (28.6) | |||
| Metastases (lung and brain excluded) | No | 19 (82.6) | 4 (17.4) | 1.187 (0.180–7.843) | 1.000 |
| Yes | 8 (80.0) | 2 (20.0) | |||
| Number of metastases | 1–4 | 25 (80.6) | 6 (19.4) | 0 | 1.000 |
| 5–8 | 2 (100.0) | 0 (0.0) | |||
| FIGO score | <12 | 7 (87.5) | 1 (12.5) | 1.750 (0.173–17.686) | 1.000 |
| ≥12 | 20 (80.0) | 5 (20.0) | |||
| Craniotomy in our center | No | 14 (70.0) | 6 (30.0) | 0 | 0.060 |
| Yes | 13 (100.0) | 0 (0.0) | |||
| Previous failed chemotherapy | No | 23 (92.0) | 2 (8.0) | 11.500 (1.553–85.154) | 0.020 |
| Yes | 4 (50.0) | 4 (50.0) | |||
| Interval from craniotomy to chemotherapy (wk) | >1 | 13 (68.4) | 6 (31.6) | 0 | 0.027 |
| ≤1 | 14 (100.0) | 0 (0.0) | |||
| Intrathecal MTX injection | Yes | 25 (80.6) | 6 (19.4) | 0 | 1.000 |
| No | 2 (100.0) | 0 (0.0) |
Values are presented as number (%).
β-hCG, β-human chorionic gonadotropin; FIGO, International Federation of Gynecology and Obstetrics.